Subject: PSID Adds Biodefense Expert to Board of Advisors

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
PSID Adds Biodefense Expert to Board of Advisors
Hot Stock to WatchHot Stock to Watch

Company: PositiveID Corporation (OTCQB: PSID)


Price: 0.0956

Change (%): - 0.0084 (8.05)

Volume: 40,099
PSID Chart

PositiveID Adds GenArraytion CEO R. Paul Schaudies, Ph.D. to its Board of Advisors

GenArraytion Developed the First Commercially Available, Multi-Target Zika Virus Assay, which PositiveID Implemented on Its Firefly Dx Prototype System and Successfully Detected the Zika Virus

DELRAY BEACH, Fla., Aug. 02, 2016 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has added Dr. R. Paul Schaudies, the CEO and co-founder of GenArraytion, Inc. and an internationally recognized expert in biodefense, biotechnology and nanotechnology, to its Board of Advisors.

PositiveID’s Firefly Dx is designed to be a fully automated, lab quality, real-time device able to detect bio-threats at the point of need in minutes instead of hours. Firefly Dx has successfully detected multiple pathogens including Zika, a fever-causing virus transmitted by the Aedes Aegypti mosquito that can cause microcephaly, a serious congenital condition in which babies are born with head and brain abnormalities.

GenArraytion self-funded the development of the first commercially available, multi-target polymerase chain reaction (PCR)-based molecular test to identify the Zika virus, its Aedes Aegypti MultiFLEX™ PCR test, which PositiveID has successfully implemented on its Firefly Dx PCR breadboard prototype pathogen detection system (“prototype system”) to detect the Zika virus. GenArraytion’s MultiFLEX™ molecular assays are readily configurable, highly specific and sensitive multiplex PCR assays ready for use in real-time and bead-based end point platforms, and are developed for clinical pathogens and veterinary disease agents as well as food or water-borne pathogens and biological threats.

Dr. Schaudies has over 20 years of experience as a corporate management executive. He has served on over a dozen National Research Council committees as well as advisory committees for many US Government agencies including Defense Advanced Research Projects Agency and Department of Energy. Dr. Schaudies was a primary science advisor to the Environmental Protection Agency On-Scene Coordinator, the Sergeant at Arms of the Senate and House of Representatives and Incident Commander of the 2001 anthrax incident in Washington, DC.

As a US Army Officer, Dr. Schaudies supported the United Nations as a United Nations Special Commission inspector in Iraq. He was an assistant vice president and division manager for Biological and Chemical Defense at Science Applications International Corporation (SAIC) for nine years. He spent 13 years as an active duty US Army officer and retired as a Lieutenant Colonel in the United States Army Reserve. Dr. Schaudies was the program manager for Biological and Chemical Defense Research in the Central Measurement and Signature Intelligence Office at the Defense Intelligence Agency, and a Senior Researcher at the Walter Reed Army Institute of Research.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks